ASGCT 2024 LSR Poster

May

5

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Apr

27

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Mar

27

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference